A monofunctional Pt(II) complex combats triple negative breast cancer by triggering lysosome-dependent cell death.
Xiaomin ShenYue PengZidong YangRenhao LiHaixia ZhouXiaoxia YeZhong HanXiangchao ShiPublished in: Dalton transactions (Cambridge, England : 2003) (2024)
Monofunctional Pt(II) complexes with potent efficacy to overcome the drawbacks of current platinum drugs represent a promising therapeutic approach for triple negative breast cancer (TNBC). A heterocyclic-ligated monofunctional Pt(II) complex PtL with a unique action of mode was designed and investigated. PtL induced DNA single-strand breaks and caused genomic instability in TNBC cells. Mechanism studies demonstrated that PtL disrupted lysosomal acidity and function, which in turn triggered lysosome-dependent cell death. Furthermore, PtL showed convincing suppression in the tube forming and cell migratory abilities against the metastatic potential of TNBC cells. The synthesis and investigation of PtL revealed its potential value as an anti-TNBC drug and extended the family of monofunctional Pt(II) complexes.
Keyphrases
- cell death
- cell cycle arrest
- induced apoptosis
- fluorescent probe
- single cell
- living cells
- small cell lung cancer
- pi k akt
- endoplasmic reticulum stress
- high glucose
- gene expression
- squamous cell carcinoma
- diabetic rats
- cell therapy
- dna methylation
- high resolution
- mesenchymal stem cells
- circulating tumor
- cell proliferation
- copy number
- cell free
- genome wide
- adverse drug
- human health
- electronic health record